Alibion
Allschwil
About Alibion
Alibion was born to bring new drug discoveries out of academic labs and closer to patients. Hundreds of new therapies are developed each year by academic groups. Many of these new therapies will, regrettably, never start preclinical and clinical testing due a lack of sufficient early stage development partners. This creates an immense need and a great opportunity. Alibion comes to close this gap. They accelerate the development of therapeutics through early stages. Their efforts are focused on identifying promising novel therapeutics and pooling the necessary resources to drive these compounds out of the labs and into late-stage development. They strive to improve patient outcomes worldwide by bringing innovative therapeutics closer to patients.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $10.1K
- Last round: Grant (Jul 2019)
- Website: alibion.com
- Phone: +41 79 549 0242
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/alibion-2240200 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.